普米克令舒联合特布他林在支气管扩张中的治疗作用观察

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (35 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To observe the therapeutical effect of Budesonide Suspension for Inhalation (Pulmicort Respules)combined with Terbutaline in bronchiectasis. Methods A total of 60 patients with bronchiectasis who were admitted to People′s Hospital of Pingxiang City from February 2016 to October 2019 were selected as the research objects and divided into the control group and the observation group by random number table method, with 30 cases in each group.The control group was treated with routine medicine, and the observation group was treated with Pulmicort Respules combined with Terbutaline. The clinical efficacy, scores of clinical symptoms (cough, sputum volume, viscous sputum),the levels of inflammatory markers (C-reactive protein [CRP], procalcitonin [PCT], fibrinogen) and length of hospital stay were compared between the two groups after 7 d of treatment. Results The total effective rate of the observation group (93.33%) was higher than that of the control group (73.33%), and the difference was statistically significant (P＜0.05). The scores of cough, sputum volume and viscous sputum of the observation group were lower than those of the control group, and the differences were statistically significant (P＜0.05). The levels of CRP, PCT and fibrinogen in the observation group were lower than those of the control group, and the differences were statistically significant (P＜0.05).The length of hospital stay of the observation group was shorter than that of the control group, and the difference was statistically significant (P＜0.05). Conclusion The effect of Pulmicort Respules combined with Terbutaline in treatment of patients with bronchiectasis was significant, it can improve the clinical symptoms, eliminate the inflammation, and shorten the length of hospital stay.

Key words： Budesonide Suspension for Inhalation (Pulmicort Respules) Terbutaline Bronchiectasis Improvement of symptoms Sputum volume

Received: 13 March 2020

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2020/V27/I29/42

[1]	胡红庆.普米克令舒联合可比特雾化吸入治疗毛细支气管炎的效果观察[J].世界临床医学，2016，10（20）：102.
[2]	樊永恒.联用普米克令舒和可必特对哮喘性支气管炎患儿进行治疗的效果评析[J].当代医药论丛，2016，14（10）：137-138.
[3]	王蔚文.临床疾病诊断与疗效判断标准[M].北京：科学技术文献出版社，2010：127-128.
[4]	粟芷华.普米克令舒联合博利康尼氧气雾化吸入治疗小儿毛细支气管炎的临床效果分析[J].北方药学，2016，13（8）：38-39.
[5]	曾振华，叶展菲.普米克令舒治疗小儿哮喘急性发作的疗效及其对肺功能的影响分析[J].临床医学工程，2016，23（2）：177-178.
[6]	唐辉英，宋萍，付丹.闭塞性细支气管炎患儿的临床特点和肺部CT 特征分析[J].中国当代医药，2018，25（20）：69-71.
[7]	李丽君.普米克令舒联合特布他林雾化治疗小儿毛细支气管炎[J].中国现代医生，2012，50（7）：83-84.
[8]	刘阳.普米克令舒联合博利康尼氧气雾化吸入治疗小儿毛细支气管炎的临床研究[J].中国医药指南，2015，9（31）：142.
[9]	钟和悦.普米克令舒联合孟鲁司特在小儿支气管哮喘治疗中的应用分析[J].中国实用医刊，2016，43（11）：105-107.
[10]	吴涛.普米克令舒联合盐酸氨溴索对支气管哮喘患者气道炎症的影响[J].中国合理用药探索，2019，16（5）：137-139.
[11]	赵忠宁.普米克令舒联合博利康尼氧气雾化吸入治疗小儿毛细支气管炎的临床疗效分析[J].中外医疗，2019，38（22）：106-108.
[12]	吴珺瑛.沙丁胺醇联合普米克令舒对哮喘急性发作患儿临床症状改善的作用分析[J].基层医学论坛，2016，20（32）：4530-4531.
[13]	陈勇，叶永青，刘国栋，等.普米克令舒联合特布他林治疗慢阻肺急性加重期的疗效观察[J].实用中西医结合临床，2016，16（12）：6-7.
[14]	赵辉，李研.普米克令舒和万托林联合甲强龙治疗小儿毛细支气管炎的临床疗效[J].临床合理用药杂志，2017，10（33）：53-55.
[15]	蒋锐.普米克令舒联合万托林雾化吸入对小儿喘息型肺炎的疗效及TNF-α、HS-CRP 的影响[J].黑龙江医药，2018，31（3）：557-558.